EGFR and neoplasm: In an in vitro study, Hata et al. documented the restorations of late-emerging T790M cells’ sensitivity to third-generation EGFR-TKIs thanks to the treatment of tumour cells with navitoclax, an inhibitor of the antiapoptotic factors BCL-2 and BCL-xL [95].